CheckMate 9ER was a worldwide, open-label, phase III trial that enrolled adults with untreated advanced or metastatic RCC to compare the efficacy and safety of the combination of nivolumab (a PD-1 checkpoint inhibitor) and cabozantinib (a VEGFR/MET/AXL tyrosine kinase inhibitor) against sunitinib monotherapy [79]. Here, PDCD1 is linked to renal cell carcinoma.